antibodies -online.com





anti-HLAG antibody

2 Images

10

Publications



Go to Product page

()	11	\sim	rv		۱ ۸
	1 \ /	┙	I \/	╙	1/1

Quantity:	0.1 mg	
Target:	HLAG	
Reactivity:	Human	
Host:	Mouse	
Clonality:	Monoclonal	
Conjugate:	This HLAG antibody is un-conjugated	
Application:	ELISA, Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro))	
Product Details		
Immunogen:	HLA-B27 transgenic mice were imunized with H-2 identical murine cells transfected with and	
	expressing genes encoding HLA-G and human beta2-microglobulin.	
Clone:	87G	
Isotype:	lgG2a	
Specificity:	The antibody 87G recognizes both membrane-bound and soluble forms of HLA-G (HLA-G1 and	
	HLA-G5). HLA-G belongs to the MHC Class I molecules (MHC Class Ib, nonclassical) and it is	
	expressed on the surface of trophoblast cells.	
No Cross-Reactivity:	Mouse, Rat	
Cross-Reactivity (Details):	Human	
Purification:	Purified by protein-A affinity chromatography.	
Purity:	> 95 % (by SDS-PAGE)	

Target Details

Target:	HLAG			
Alternative Name:	HLA-G (HLAG Products)			
Background:	Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to			
	MHC class I glycoproteins, plays important roles in both physiological and pathological			
	immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and			
	some other immune cells. It also induces regulatory T cells and anti-inflammatory			
	macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for			
	immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and			
	other. On the other hand, it is expressed in many solid and hematologic malignancies, where it			
	contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an			
	important prognostic factor regarding a poor clinical outcome. Unlike most other MHC			
	glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen			
	presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among			
	other, HLA-G can promote Th2 immunological response and downregulate Th1 immunologica			
	response. For its benefits regarding allograft tolerance, including embryo implantation, soluble			
	HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the			
	process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are			
	decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have			
	improved allograft acceptance. On the other hand, increased sHLA-G can also indicate			
	presence of malignant (sometimes also of benign) tumor cells. Another important topic is			
	induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell			
	surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect.			
	Monitoring of HLA-G in patients thus has a wide usage.			
Gene ID:	3135			
UniProt:	P17693			
Pathways:	Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process,			
	Cancer Immune Checkpoints			
Application Details				
Application Notes:	Flow cytometry: Extracellular and intracellular staining, Recommended dilution: 2 µg/mL,			
	positive control: JEG-3 human choriocarcinoma epithelial cell line.			
	Immunohistochemistry (frozen sections): Recommended dilution: 10 µg/mL, incubation: 20 m			
	at 25 °C, positive tissue: extravillous cytotrophoblast.			

Application Details

ELISA: Recommended dilution: 1 µg/mL, positive control: JEG-3 human choriocarcinoma
epithelial cell line. The antibody 87G has been tested as the capture antibody in a sandwich
ELISA for analysis of human HLA-G in combination with antibody W6/32.

Restrictions:

For Research Use only

Handling

Concentration:	1 mg/mL	
Buffer:	Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide	
Preservative:	Sodium azide	
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.	
Storage:	4 °C	
Storage Comment:	Store at 2-8°C. Do not freeze.	

Publications

Product cited in:

LeMaoult, Caumartin, Daouya, Favier, Le Rond, Gonzalez, Carosella: "Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells." in: **Blood**, Vol. 109, Issue 5, pp. 2040-8, (2007) (PubMed).

Shobu, Sageshima, Tokui, Omura, Saito, Nagatsuka, Nakanishi, Hayashi, Hatake, Ishitani: "The surface expression of HLA-F on decidual trophoblasts increases from mid to term gestation." in: **Journal of reproductive immunology**, Vol. 72, Issue 1-2, pp. 18-32, (2006) (PubMed).

Rouas-Freiss, Moreau, Ferrone, Carosella: "HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?" in: **Cancer research**, Vol. 65, Issue 22, pp. 10139-44, (2005) (PubMed).


Hackmon, Hallak, Krup, Weitzman, Sheiner, Kaplan, Weinstein: "HLA-G antigen and parturition: maternal serum, fetal serum and amniotic fluid levels during pregnancy." in: **Fetal diagnosis and therapy**, Vol. 19, Issue 5, pp. 404-9, (2004) (PubMed).

Sageshima, Ishitani, Omura, Akasaki, Umekage, Katabuchi, Okamura, Hatake: "Necrotic feature of the trophoblasts lacking HLA-G expression in normal and pre-eclamptic placentas." in:

American journal of reproductive immunology (New York, N.Y.: 1989), Vol. 49, Issue 3, pp. 174-82, (2003) (PubMed).


There are more publications referencing this product on: Product page

Images



Flow Cytometry

Image 1. Separation of HLA-G transfected LCL cells (red-filled) from non-transfected LCL cells (black-dashed) in flow cytometry analysis (surface staining) stained using anti-HLA-G (87G) purified antibody (concentration in sample 10 μ g/mL, GAM APC).



Activity Assay

Image 2. Analysis of cytolytical activity Analysis of cytolytical activity of human polyclonal NK cells on target melanoma cells. Blocking of HLA-G1 on transfectants with anti-human HLA-G (87G) restored specific lysis. Target cells: M8 cell line transfected with empty vector (column 1) and with HLA-G1 cDNA (columns 2-6). Blocking antibodies: Column 1-2: none Column 3: Isotype mouse IgG2a control Column 4: anti-human HLA-G (87G) purified Column 5: anti-human HLA-G (87G) F(ab)2 fragment Column 6: anti-human HLA-G (MEM-G/9